{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:50:18Z","timestamp":1793742618494,"version":"4.6.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370724"],"award-info":[{"award-number":["82370724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019558","name":"Qingdao Key Health Discipline Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019558","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Qingdao Key Clinical Specialty Elite Discipline project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01584-4","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T07:18:42Z","timestamp":1739603922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments"],"prefix":"10.1007","volume":"25","author":[{"given":"Yongzheng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"1584_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101091","author":"Y Deng","year":"2024","unstructured":"Deng Y, Kang H, Xiang H, Nan Y, Hu J, Meng Q, Zhao H, Wang Q, Fang J, Xu J, Wang X. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101091.","journal-title":"JHEP Rep"},{"key":"1584_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12879-024-09177-4","volume":"24","author":"J Altinawe","year":"2024","unstructured":"Altinawe J, Akkawi ME, Kharrat Helu N, Hassan Q, Nattouf AH. Seroprevalence and risk factors of HBV, HCV and HIV among hemodialysis patients: a multicenter cross-sectional study from Damascus Syria. BMC Infect Dis. 2024;24:289.","journal-title":"BMC Infect Dis"},{"key":"1584_CR3","doi-asserted-by":"crossref","first-page":"e0290917","DOI":"10.1371\/journal.pone.0290917","volume":"19","author":"B Dzudzor","year":"2024","unstructured":"Dzudzor B, Nsowah KK, Agyemang S, Vento S, Amarh V, Boima V, Tachi K. Overt and occult hepatitis B virus infection detected among chronic kidney disease patients on haemodialysis at a Tertiary Hospital in Ghana. PLoS ONE. 2024;19:e0290917.","journal-title":"PLoS ONE"},{"key":"1584_CR4","first-page":"2984","volume":"104","author":"Branch of Transplantation of the Chinese Medical Association","year":"2024","unstructured":"Branch of Transplantation of the Chinese Medical Association. Clinical guidelines for hepatitis B virus infection in kidney transplant recipients. Zhonghua Yi Xue Za Zhi. 2024;104:2984\u201394.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1584_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3451544","author":"X Sheng","year":"2022","unstructured":"Sheng X, Zhou J, Gu X, Wang H. The effect of artificial liver support system on prognosis of HBV-derived hepatorenal syndrome: a retrospective cohort study. Dis Markers. 2022. https:\/\/doi.org\/10.1155\/2022\/3451544.","journal-title":"Dis Markers"},{"key":"1584_CR6","doi-asserted-by":"crossref","first-page":"1031790","DOI":"10.3389\/fphar.2022.1031790","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yuan W, Fang M, Guo H, Zhang X, Mei X, et al. Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: early prediction and prognostic implications. Front Pharmacol. 2023;13:1031790.","journal-title":"Front Pharmacol"},{"key":"1584_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60861","author":"N Mohammad","year":"2024","unstructured":"Mohammad N, Khan D. Efficacy of Sofosbuvir and Velpatasvir combination in the treatment of hepatitis C virus (HCV) in chronic kidney disease (CKD) patients. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.60861.","journal-title":"Cureus"},{"key":"1584_CR8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.14218\/JCTH.2021.00082","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang X, Xu F, Li D, Yang H, Sun N, Fan YC, Yang X. Risk factors of chronic kidney disease in chronic hepatitis B: a hospital-based case-control study from China. J Clin Transl Hepatol. 2021;10:238.","journal-title":"J Clin Transl Hepatol"},{"key":"1584_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000509088","volume":"7","author":"Y Zhuang","year":"2021","unstructured":"Zhuang Y, Liu B, Yu Y, Guan T, Zheng Z, Chen A. Severity of intrarenal arterial lesions can predict the clinical prognosis of hepatitis B virus-associated glomerulonephritis: a retrospective study. Kidney Dis. 2021;7:67\u201378.","journal-title":"Kidney Dis"},{"key":"1584_CR10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000522537","volume":"8","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yu XJ, An CW, Yong ZH, Wang SX, Zhou FD, Zhao MH. Clinicopathological spectrum of cryoglobulinemic glomerulonephritis without evidence of autoimmunity disorders: a retrospective study from a single institute of China. Kidney Dis. 2022;8:253\u201364.","journal-title":"Kidney Dis"},{"key":"1584_CR11","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2147\/IJGM.S318087","volume":"14","author":"F Yu","year":"2021","unstructured":"Yu F, Li G, Hao W, Hu W. Hepatitis B virus-related glomerulonephritis with positive and negative serum HBsAg: different clinicopathologic characteristics of two clinical subtypes. Int J Gen Med. 2021;14:3069\u201377.","journal-title":"Int J Gen Med"},{"key":"1584_CR12","doi-asserted-by":"crossref","first-page":"e20200154","DOI":"10.1590\/1678-9199-jvatitd-2020-0154","volume":"27","author":"GFD Mata","year":"2021","unstructured":"Mata GFD, Fernandes DE, Luciano EDP, Sales GTM, Riguetti MTP, Kirsztajn GM. Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV. J Venom Anim Toxins Incl Trop DiS. 2021;27:e20200154.","journal-title":"J Venom Anim Toxins Incl Trop DiS"},{"key":"1584_CR13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13578-022-00835-1","volume":"12","author":"H Guan","year":"2022","unstructured":"Guan H, Zhu N, Tang G, Du Y, Wang L, Yuan W. DNA methyltransferase 1 knockdown reverses PTEN and VDR by mediating demethylation of promoter and protects against renal injuries in hepatitis B virus-associated glomerulonephritis. Cell Biosci. 2022;12:98.","journal-title":"Cell Biosci"},{"key":"1584_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/infdis\/jiad273","volume":"229","author":"CY Jung","year":"2024","unstructured":"Jung CY, Jung HY, Kim HW, Ryu GW, Lee JI, Ahn SH, Kim SU, Kim BS. Fibrotic burden in patients with hepatitis B virus-related cirrhosis is independently associated with poorer kidney outcomes. J Infect Dis. 2024;229:108\u201316.","journal-title":"J Infect Dis"},{"key":"1584_CR15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s40620-021-01004-2","volume":"34","author":"K Wang","year":"2021","unstructured":"Wang K, Yu Z, Huang Y, Yang K, He T, Xiao T, et al. Clinicopathological features, risk factors, and outcomes of immunoglobulin A nephropathy associated with hepatitis B virus infection. J Nephrol. 2021;34:1887\u201396.","journal-title":"J Nephrol"},{"key":"1584_CR16","first-page":"434","volume":"21","author":"XZ Duan","year":"2013","unstructured":"Duan XZ, Hu JH, Li C, Liu FF, Liu XY, Tong JJ, Xin SJ. Relation between serum levels of high mobility group box 1 and hepatitis B virus-related acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi. 2013;21:434\u20137.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"1584_CR17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107:88\u201397.","journal-title":"J Clin Endocrinol Metab"},{"key":"1584_CR18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4103\/jfmpc.jfmpc_1017_21","volume":"11","author":"D Raina","year":"2022","unstructured":"Raina D, Rawat N, Pandita AK. Prevalence of hepatitis B and hepatitis C in patients undergoing hemodialysis at a teaching hospital in Uttarakhand. J Family Med Prim Care. 2022;11:1348\u201353.","journal-title":"J Family Med Prim Care"},{"key":"1584_CR19","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s11255-023-03587-0","volume":"55","author":"L Marc","year":"2023","unstructured":"Marc L, Mihaescu A, Lupusoru R, Schiller O, Bob F, Chisavu L, et al. Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers. Int Urol Nephrol. 2023;55:2951\u20138.","journal-title":"Int Urol Nephrol"},{"key":"1584_CR20","doi-asserted-by":"crossref","first-page":"e15389","DOI":"10.1111\/ctr.15389","volume":"38","author":"CY Chiu","year":"2024","unstructured":"Chiu CY, Brumble LM, Vikram HR, Watt KD, Beam E. Hepatitis B virus reactivation in non-liver solid organ transplantation: incidence and risk analysis. Clin Transplant. 2024;38:e15389.","journal-title":"Clin Transplant"},{"key":"1584_CR21","doi-asserted-by":"crossref","first-page":"e13170","DOI":"10.1111\/tid.13170","volume":"21","author":"ML Cambier","year":"2019","unstructured":"Cambier ML, Canestri A, Lependeven C, Peltier J, Mesnard L, Dahan K. Hepatitis B virus reactivation during belatacept treatment after kidney transplantation. Transpl Infect Dis. 2019;21:e13170.","journal-title":"Transpl Infect Dis"},{"key":"1584_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.akdh.2023.04.003","volume":"30","author":"P Sharma","year":"2023","unstructured":"Sharma P, Sawtell R, Wang Q, Sise ME. Management of hepatitis C virus and hepatitis B virus infection in the setting of kidney disease. Adv Kidney Dis Health. 2023;30:343\u201355.","journal-title":"Adv Kidney Dis Health"},{"key":"1584_CR23","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.3748\/wjg.v27.i26.4104","volume":"27","author":"H Yeh","year":"2021","unstructured":"Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: pathophysiology, prognosis, and treatment challenges. World J Gastroenterol. 2021;27:4104\u201342.","journal-title":"World J Gastroenterol"},{"key":"1584_CR24","first-page":"126532","volume":"2015","author":"JJ Yoo","year":"2015","unstructured":"Yoo JJ, Lee JH, Yoon JH, Lee M, Lee DH, Cho Y, Jang ES, Cho EJ, Yu SJ, Kim YJ, Lee HS. Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in Korean patients with chronic hepatitis B. Gastroenterol Res and Pract. 2015;2015:126532.","journal-title":"Gastroenterol Res and Pract"},{"key":"1584_CR25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.23876\/j.krcp.20.082","volume":"39","author":"D Bhatia","year":"2020","unstructured":"Bhatia D, Capili A, Choi ME. Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches. Kidney Res Clin Pract. 2020;39:244\u201358.","journal-title":"Kidney Res Clin Pract"},{"key":"1584_CR26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/ckj\/sfaa026","volume":"14","author":"A Nikolopoulou","year":"2020","unstructured":"Nikolopoulou A, Teixeira C, Cook HT, Roufosse C, Cairns THD, Levy JB, et al. Membranous nephropathy associated with viral infection. Clin Kidney J. 2020;14:876\u201383.","journal-title":"Clin Kidney J"},{"key":"1584_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-9-1","volume":"9","author":"L Zhang","year":"2012","unstructured":"Zhang L, Meng H, Han X, Han C, Sun C, Ye F, Jin X. The relationship between HBV serum markers and the clinicopathological characteristics of hepatitis B virus-associated glomerulonephritis (HBV-GN) in the northeastern Chinese population. Virol J. 2012;9:1\u20139.","journal-title":"Virol J"},{"key":"1584_CR28","doi-asserted-by":"crossref","first-page":"e13055","DOI":"10.1111\/cpr.13055","volume":"54","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Fu B, Chen P, Li Q, Ouyang Q, Zhang C, Cai G, Wu L, Chen X. Activated mesangial cells induce glomerular endothelial cells proliferation in rat anti-Thy-1 nephritis through VEGFA\/VEGFR2 and Angpt2\/Tie2 pathway. Cell Prolif. 2021;54:e13055.","journal-title":"Cell Prolif"},{"key":"1584_CR29","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.38.218.21059","author":"I Agrebi","year":"2021","unstructured":"Agrebi I, Kammoun K, Dammak N, Hachicha J, Boudawara T, Jarraya F, Hmida MB. Primary membranoproliferative glomerulonephritis in Sfax, Tunisia: epidemiologic profile and prognostic factors. Pan Afr Med J. 2021. https:\/\/doi.org\/10.11604\/pamj.2021.38.218.21059.","journal-title":"Pan Afr Med J"},{"key":"1584_CR30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5144\/0256-4947.1993.420","volume":"13","author":"TK Mattoo","year":"1993","unstructured":"Mattoo TK, Al-Sowailem AM. Spectrum of renal pathology in 100 selected children with nephrotic syndrome. Ann Saudi Med. 1993;13:420\u20132.","journal-title":"Ann Saudi Med"},{"key":"1584_CR31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4103\/0377-4929.42506","volume":"51","author":"S Kumar","year":"2008","unstructured":"Kumar S, Singh RG, Tapas S, Prakash J, Garbyal RS. Mesangioproliferative glomerulonephritis: an important glomerulonephritis in nephrotic syndrome of young adult. Indian J Pathol Microbiol. 2008;51:337\u201341.","journal-title":"Indian J Pathol Microbiol"},{"key":"1584_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-13-1","volume":"13","author":"Y Li","year":"2012","unstructured":"Li Y, Wang J, Zhu X, Feng Q, Li X, Feng X. Urinary protein markers predict the severity of renal histological lesions in children with mesangial proliferative glomerulonephritis. BMC nephrol. 2012;13:1\u201310.","journal-title":"BMC nephrol"},{"key":"1584_CR33","first-page":"376","volume":"50","author":"XY Lei","year":"2012","unstructured":"Lei XY, Gao X, Yang JL, Sun YH, Sai YP, Yuan H. Relationship between B\/C genotype of hepatitis B virus and hepatitis B virus related-nephritis in children. Zhonghua Er Ke Za Zhi. 2012;50:376\u20139.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"1584_CR34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1071\/SH17168","volume":"15","author":"I Gentile","year":"2018","unstructured":"Gentile I, Fusco F, Buonomo AR, Scotto R, Zappulo E, Pinchera B, et al. Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. Sex Health. 2018;15:408\u201312.","journal-title":"Sex Health"},{"key":"1584_CR35","doi-asserted-by":"crossref","first-page":"845767","DOI":"10.3389\/fimmu.2022.845767","volume":"13","author":"Q Liu","year":"2022","unstructured":"Liu Q, Liu J, Lin B, Zhang Y, Ma M, Yang M, Qin X. Novel biomarkers in membranous nephropathy. Front Immunol. 2022;13:845767.","journal-title":"Front Immunol"},{"key":"1584_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-9-1","volume":"9","author":"H Lu","year":"2012","unstructured":"Lu H, Zhu H, Zhou J. S gene mutations of HBV in children with HBV-associated glomerulonephritis. Virol J. 2012;9:1\u20136.","journal-title":"Virol J"},{"key":"1584_CR37","first-page":"526","volume":"29","author":"YE Zhang","year":"1990","unstructured":"Zhang YE, Guo MY, Ying YY. Further study on the immunopathology of hepatitis B virus associated glomerulonephritis. Zhonghua Nei Ke Za Zhi. 1990;29:526\u20139.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"1584_CR38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/ckj\/sfab069","volume":"14","author":"S Sethi","year":"2021","unstructured":"Sethi S. Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases. Clin Kidney J. 2021;14:2166\u20139.","journal-title":"Clin Kidney J"},{"key":"1584_CR39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfab281","volume":"38","author":"M Noris","year":"2023","unstructured":"Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant. 2023;38:283\u201390.","journal-title":"Nephrol Dial Transplant"},{"key":"1584_CR40","doi-asserted-by":"crossref","first-page":"1128393","DOI":"10.3389\/fmed.2023.1128393","volume":"10","author":"H Zhang","year":"2023","unstructured":"Zhang H, Deng Z, Wang Y. Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy. Front Med. 2023;10:1128393.","journal-title":"Front Med"},{"key":"1584_CR41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fmed.2020.00293","volume":"30","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Hou J, Hasnain H, Arman F, Selamet U, Wilson J, Olanrewaju S, Zuckerman JE, Barsoum M, Yabu JM, Kurtz I. Diverse clinical presentations of C3 dominant glomerulonephritis. Front Med. 2020;30:293.","journal-title":"Front Med"},{"key":"1584_CR42","doi-asserted-by":"crossref","first-page":"715704","DOI":"10.3389\/fimmu.2021.715704","volume":"11","author":"MA Michels","year":"2021","unstructured":"Michels MA, Van de Kar NC, Van Kraaij SA, Sarlea SA, Gracchi V, Engels FA, Dorresteijn EM, van der Deure J, Duineveld C, Wetzels JF, van den Heuvel LP. Different aspects of classical pathway overactivation in patients with C3 glomerulopathy and immune complex-mediated membranoproliferative glomerulonephritis. Front Immunol. 2021;11:715704.","journal-title":"Front Immunol"},{"key":"1584_CR43","first-page":"e01365","volume":"12","author":"L Wang","year":"2024","unstructured":"Wang L, Wang C, Wang X, Cao Y, Guo X, Ye Z. Hepatitis B virus-targeting sodium taurocholate cotransporting polypeptide mediates HBV infection and damage in human renal podocytes. Microbiol Spectr. 2024;12:e01365-e1423.","journal-title":"Microbiol Spectr"},{"key":"1584_CR44","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3748\/wjg.v9.i9.2004","volume":"9","author":"NS Wang","year":"2003","unstructured":"Wang NS, Wu ZL, Zhang YE, Guo MY, Liao LT. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol. 2003;9:2004.","journal-title":"World J Gastroenterol"},{"key":"1584_CR45","doi-asserted-by":"crossref","first-page":"1327149","DOI":"10.3389\/fphar.2024.1327149","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Yang X, Feng M, Yu Y, Hu Y, Jiang W. Exosomal miR-223-3p from bone marrow mesenchymal stem cells targets HDAC2 to downregulate STAT3 phosphorylation to alleviate HBx-induced ferroptosis in podocytes. Front Pharmacol. 2024;15:1327149.","journal-title":"Front Pharmacol"},{"key":"1584_CR46","first-page":"1714","volume":"103","author":"M Feng","year":"2023","unstructured":"Feng M, An Q, Yu Y, Chen Y, Yang X, Li B, et al. Mechanism of podocyte pyroptosis aggravated by up-regulation of phospholipase A2 receptor by hepatitis B virus X protein. Zhonghua Yi Xue Za Zhi. 2023;103:1714\u201323.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1584_CR47","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","volume":"71","author":"S Zhu","year":"2019","unstructured":"Zhu S, Dong Y, Wang L, Liu W, Zhao P. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. J Hepatol. 2019;71:871\u20135.","journal-title":"J Hepatol"},{"key":"1584_CR48","first-page":"53","volume":"52","author":"A Mason","year":"2006","unstructured":"Mason A. Role of viral replication in extrahepatic syndromes related to hepatitis B virus infection. Minerva Gastroenterol Dietol. 2006;52:53\u201366.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"1584_CR49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/17474124.2020.1717948","volume":"14","author":"Y Liu","year":"2020","unstructured":"Liu Y, Shi C, Fan J, Wang B, Li G. Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Rev Gastroenterol Hepatol. 2020;14:113\u201325.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1584_CR50","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.3390\/jcm11216247","volume":"11","author":"C Mazzaro","year":"2022","unstructured":"Mazzaro C, Adinolfi LE, Pozzato G, Nevola R, Zanier A, Serraino D, Andreone P, Fenoglio R, Sciascia S, Gattei V, Roccatello D. Extrahepatic manifestations of chronic HBV infection and the role of antiviral therapy. J Clin Med. 2022;11:6247.","journal-title":"J Clin Med"},{"key":"1584_CR51","first-page":"843","volume":"112","author":"L Wang","year":"2020","unstructured":"Wang L, Xie B, Zheng Q, Xu L, Ye Z. Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy. Rev Esp Enferm Dig. 2020;112:843\u20139.","journal-title":"Rev Esp Enferm Dig"},{"key":"1584_CR52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/hepr.13982","volume":"54","author":"M Tanaka","year":"2024","unstructured":"Tanaka M, Akahane T, Kawaratani H, Yorioka N, Koizumi A, Asada S, et al. Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B. Hepatol Res. 2024;54:252\u201360.","journal-title":"Hepatol Res"},{"key":"1584_CR53","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s10157-023-02351-z","volume":"27","author":"Y Yu","year":"2023","unstructured":"Yu Y, Xu L, Xu T, Yang C, Bu Q, Zhang W, et al. Efficacy and safety of entecavir for hepatitis B virus-associated glomerulonephritis with renal insufficiency. Clin Exp Nephrol. 2023;27:680\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"1584_CR54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ID9.0000000000000128","volume":"4","author":"W Zhao","year":"2024","unstructured":"Zhao W. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (text extract): executive summary. Infect Dis Immun. 2024;4:103\u20135.","journal-title":"Infect Dis Immun"},{"key":"1584_CR55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-0029-1244814","volume":"135","author":"M Cornberg","year":"2010","unstructured":"Cornberg M, Manns MP. Entecavir\u2014options and obstacles of an effective treatment for chronic hepatitis B. Dtsch Med Wochenschr. 2010;135:32\u20137.","journal-title":"Dtsch Med Wochenschr"},{"key":"1584_CR56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12876-023-03027-4","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23:384.","journal-title":"BMC Gastroenterol"},{"key":"1584_CR57","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.12998\/wjcc.v11.i34.8139","volume":"11","author":"G-C Yuan","year":"2023","unstructured":"Yuan G-C, Chen A-Z, Wang W-X, Yi X-L, Tu L, Peng F, et al. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir. World J Clin Cases. 2023;11:8139\u201346.","journal-title":"World J Clin Cases"},{"key":"1584_CR58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","volume":"12","author":"R Gish","year":"2012","unstructured":"Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1584_CR59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jgh.12416","volume":"29","author":"RN Chien","year":"2014","unstructured":"Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, et al. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na\u00efve Taiwanese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014;29:185\u201392.","journal-title":"J Gastroenterol Hepatol"},{"key":"1584_CR60","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clinthera.2006.02.012","volume":"28","author":"SJ Matthews","year":"2006","unstructured":"Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006;28:184\u2013203.","journal-title":"Clin Ther"},{"key":"1584_CR61","doi-asserted-by":"crossref","first-page":"e22661","DOI":"10.1371\/journal.pone.0022661","volume":"6","author":"T Nishijima","year":"2011","unstructured":"Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS ONE. 2011;6:e22661.","journal-title":"PLoS ONE"},{"key":"1584_CR62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3904\/kjim.2015.30.1.32","volume":"30","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med. 2015;30:32\u201341.","journal-title":"Korean J Intern Med"},{"key":"1584_CR63","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.3748\/wjg.v29.i33.4942","volume":"29","author":"JWY Mak","year":"2023","unstructured":"Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol. 2023;29:4942\u201361.","journal-title":"World J Gastroenterol"},{"key":"1584_CR64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1684\/vir.2022.0927","volume":"26","author":"T Foucault","year":"2022","unstructured":"Foucault T, Handala L, Paintaud G, Gaudy-Graffin C, Marlet J. Treatment of chronic hepatitis B: virological and pharmacological aspects. Virologie (Montrouge). 2022;26:228\u201339.","journal-title":"Virologie (Montrouge)"},{"key":"1584_CR65","doi-asserted-by":"crossref","first-page":"1295217","DOI":"10.3389\/fmed.2024.1295217","volume":"19","author":"S Hanser","year":"2024","unstructured":"Hanser S, Choshi J, Mokoena H, Mabhida SE, Mchiza ZJ, Moetlediwa MT, Muvhulawa N, Nkambule BB, Ndwandwe D, Nqebelele U, Kengne AP. A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy. Front Med. 2024;19:1295217.","journal-title":"Front Med"},{"key":"1584_CR66","first-page":"363","volume":"38","author":"MG Fischer","year":"2021","unstructured":"Fischer MG, Newman W, Hammer K, Rohrich M, Lo TS. Comparison of renal function between tenofovir disoproxil fumarate and other nucleos (t) ide reverse transcriptase inhibitors in patients with hepatitis B virus infection. Fed Pract. 2021;38:363.","journal-title":"Fed Pract"},{"key":"1584_CR67","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14787210.2024.2412991","volume":"22","author":"M Rodrigo","year":"2024","unstructured":"Rodrigo M, Hartley C, Wasuwanich P, Van T, Karnsakul W. From tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): perspectives in pediatric patients with chronic hepatitis B. Expert Rev Anti Infect Ther. 2024;22:1099\u2013106.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1584_CR68","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","volume":"40","author":"E Ogawa","year":"2020","unstructured":"Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578\u201389.","journal-title":"Liver Int"},{"key":"1584_CR69","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jvh.13500","volume":"28","author":"MS Farag","year":"2021","unstructured":"Farag MS, Fung S, Tam E, Doucette K, Wong A, Ramji A, et al. Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis b patients: real-world study. J Viral Hepat. 2021;28:942\u201350.","journal-title":"J Viral Hepat"},{"key":"1584_CR70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/hepr.13726","volume":"52","author":"T Hosaka","year":"2022","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, et al. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res. 2022;52:153\u201364.","journal-title":"Hepatol Res"},{"issue":"5","key":"1584_CR71","doi-asserted-by":"crossref","first-page":"e0251552","DOI":"10.1371\/journal.pone.0251552","volume":"16","author":"CQ Pan","year":"2021","unstructured":"Pan CQ, Chang TT, Bae SH, Brunetto M, Seto WK, Coffin CS, Tan SK, Mo S, Flaherty JF, Gaggar A, Nguyen MH. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS ONE. 2021;16(5):e0251552.","journal-title":"PLoS ONE"},{"key":"1584_CR72","doi-asserted-by":"crossref","first-page":"135965352412842","DOI":"10.1177\/13596535241284226","volume":"29","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Xu J, Liu D, Wang L, Ren S, Zheng S, Chen X, Qi L, Lu J. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Antivir Ther. 2024;29:13596535241284226.","journal-title":"Antivir Ther"},{"key":"1584_CR73","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","volume":"29","author":"WT Peng","year":"2023","unstructured":"Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study. World J Gastroenterol. 2023;29:5907\u201318.","journal-title":"World J Gastroenterol"},{"key":"1584_CR74","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1134\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"1584_CR75","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10461-010-9818-5","volume":"15","author":"J Raboud","year":"2011","unstructured":"Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, et al. Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav. 2011;15:1397\u2013409.","journal-title":"AIDS Behav"},{"key":"1584_CR76","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","volume":"66","author":"JW Shin","year":"2021","unstructured":"Shin JW, Jeong J, Jung SW, Lee SB, Park BR, Kim MJ, et al. Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir. Dig Dis Sci. 2021;66:1739\u201350.","journal-title":"Dig Dis Sci"},{"key":"1584_CR77","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60:1573.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"1584_CR78","first-page":"e10813","volume":"14","author":"Z Wen","year":"2014","unstructured":"Wen Z, Zhang H, Zhang M, Tan D, Li Q, Zhang H, Wu P, Deng L. Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy. Hepat Mon. 2014;14(8):e10813.","journal-title":"Hepat Mon"},{"key":"1584_CR79","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000356312","volume":"88","author":"S Koklu","year":"2013","unstructured":"Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Yilmaz B, et al. Lamivudine treatment failure risks in chronic hepatitis B patients with low viral load. Digestion. 2013;88:266\u201371.","journal-title":"Digestion"},{"key":"1584_CR80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3904\/kjim.2012.27.4.411","volume":"27","author":"IO Sun","year":"2012","unstructured":"Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, et al. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med. 2012;27:411\u20136.","journal-title":"Korean J Intern Med"},{"key":"1584_CR81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/187152609787847677","volume":"9","author":"L Stein","year":"2009","unstructured":"Stein L, Loomba R. Drug targets in hepatitis B virus infection. Infect Disord Drug Targets. 2009;9:105\u201316.","journal-title":"Infect Disord Drug Targets"},{"key":"1584_CR82","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/13543784.14.4.511","volume":"14","author":"SHB Han","year":"2005","unstructured":"Han SHB. Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005;14:511\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"31","key":"1584_CR83","doi-asserted-by":"crossref","first-page":"e11716","DOI":"10.1097\/MD.0000000000011716","volume":"97","author":"Z Yan","year":"2018","unstructured":"Yan Z, Qiao B, Zhang H, Wang Y, Gou W. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. Medicine. 2018;97(31):e11716.","journal-title":"Medicine"},{"key":"1584_CR84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12325-009-0004-y","volume":"26","author":"K Nash","year":"2009","unstructured":"Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009;26:155\u201369.","journal-title":"Adv Ther"},{"key":"1584_CR85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11096-012-9633-3","volume":"34","author":"M Wang","year":"2012","unstructured":"Wang M, Da Y, Cai H, Lu Y, Wu L, Jia J. Telbivudine myopathy in a patient with chronic hepatitis B. Int J Clin Pharm. 2012;34:422\u20135.","journal-title":"Int J Clin Pharm"},{"key":"1584_CR86","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3346\/jkms.2010.25.5.738","volume":"25","author":"IH Kim","year":"2010","unstructured":"Kim IH, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, et al. Treatment outcomes of clevudine versus lamivudine at week 48 in na\u00efve patients with HBeAg positive chronic hepatitis B. J Korean Med Sci. 2010;25:738\u201345.","journal-title":"J Korean Med Sci"},{"key":"1584_CR87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12072-014-9537-5","volume":"8","author":"WY Tak","year":"2014","unstructured":"Tak WY, Yang JM, Kim BI, Baik SK, Cheon GJ, Byun KS, et al. A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in na\u00efve chronic hepatitis B patients. Hepatol Int. 2014;8:375\u201381.","journal-title":"Hepatol Int"},{"key":"1584_CR88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5152\/tjg.2016.16085","volume":"27","author":"K Atay","year":"2016","unstructured":"Atay K, Hatemi \u0130, Canbakan B, K\u00f6ro\u011flu E, Durcan E, Yurtta\u015f B, G\u00fcltepe \u0130, \u00d6zdemir S, Tuncer M, Sonsuz A. Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B. Turk J Gastroenterol. 2016;27:279\u201383.","journal-title":"Turk J Gastroenterol"},{"key":"1584_CR89","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/jmv.23689","volume":"85","author":"L Wang","year":"2013","unstructured":"Wang L, Chen H, Fan C, Gong Z. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection. J Med Virol. 2013;85:1907\u201312.","journal-title":"J Med Virol"},{"issue":"2","key":"1584_CR90","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3350\/cmh.2014.20.2.168","volume":"20","author":"HY Woo","year":"2014","unstructured":"Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol. 2014;20(2):168.","journal-title":"Clin Mol Hepatol"},{"key":"1584_CR91","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.21225","volume":"44","author":"M Zeng","year":"2006","unstructured":"Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44:108\u201316.","journal-title":"Hepatology"},{"key":"1584_CR92","first-page":"357","volume":"42","author":"YK Cho","year":"2003","unstructured":"Cho YK, Kim BI. Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases. Korean J Gastroenterol. 2003;42:357\u201362.","journal-title":"Korean J Gastroenterol"},{"key":"1584_CR93","first-page":"484","volume":"12","author":"SH Ryu","year":"2006","unstructured":"Ryu SH, Chung YH. Resistance to adefovir in patients with chronic hepatitis B. Korean J Hepatol. 2006;12:484\u201392.","journal-title":"Korean J Hepatol"},{"issue":"1","key":"1584_CR94","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3934\/mbe.2020032","volume":"17","author":"MC Lai","year":"2020","unstructured":"Lai MC, Lian JS, Zhang WJ, Xu J, Zhou L, Zheng SS. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant. Math Biosci Eng. 2020;17(1):627\u201335.","journal-title":"Math Biosci Eng"},{"key":"1584_CR95","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2011.593507","volume":"10","author":"M Vigan\u00f2","year":"2011","unstructured":"Vigan\u00f2 M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf. 2011;10:809\u201318.","journal-title":"Expert Opin Drug Saf"},{"key":"1584_CR96","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1440-1746.2011.06852.x","volume":"27","author":"YJ Kim","year":"2012","unstructured":"Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012;27:306\u201312.","journal-title":"J Gastroenterol Hepatol"},{"key":"1584_CR97","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4274\/balkanmedj.2016.1461","volume":"34","author":"EE T\u00fct\u00fcnc\u00fc","year":"2017","unstructured":"T\u00fct\u00fcnc\u00fc EE, G\u00fcner R, G\u00fcrb\u00fcz Y, Kaya Kalem A, \u00d6zt\u00fcrk B, Hasano\u011flu \u0130, et al. adherence to nucleoside\/nucleotide analogue treatment in patients with chronic hepatitis B. Balkan Med J. 2017;34:540\u20135.","journal-title":"Balkan Med J"},{"key":"1584_CR98","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12985-024-02512-w","volume":"21","author":"Y Li","year":"2024","unstructured":"Li Y, Yang S, Li C, Ma Z, Zhang M, Zou W, et al. Efficacy of short-term Peg-IFN \u03b1-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study. Virol J. 2024;21:231.","journal-title":"Virol J"},{"key":"1584_CR99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/v11050427","volume":"11","author":"T Li","year":"2019","unstructured":"Li T, Ke Z, Liu W, Xiong Y, Zhu Y, Liu Y. Human hepatitis B virus core protein inhibits IFN\u03b1-induced IFITM1 expression by interacting with BAF200. Viruses. 2019;11:427.","journal-title":"Viruses"},{"issue":"9","key":"1584_CR100","doi-asserted-by":"crossref","first-page":"e0160437","DOI":"10.1371\/journal.pone.0160437","volume":"11","author":"Y Yang","year":"2016","unstructured":"Yang Y, Ma YP, Chen DP, Zhuo L, Li WG. A meta-analysis of antiviral therapy for hepatitis B virus-associated membranous nephropathy. PLoS ONE. 2016;11(9):e0160437.","journal-title":"PLoS ONE"},{"issue":"22","key":"1584_CR101","doi-asserted-by":"crossref","first-page":"e7021","DOI":"10.1097\/MD.0000000000007021","volume":"96","author":"S Cai","year":"2017","unstructured":"Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine. 2017;96(22):e7021.","journal-title":"Medicine"},{"key":"1584_CR102","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GL Wong","year":"2022","unstructured":"Wong GL, Gane E, Lok AS. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76:1249\u201362.","journal-title":"J Hepatol"},{"issue":"12","key":"1584_CR103","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2583::AID-CNCR14>3.0.CO;2-#","volume":"85","author":"F Ravandi-Kashani","year":"1999","unstructured":"Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer. 1999;85(12):2583\u20138.","journal-title":"Cancer"},{"key":"1584_CR104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12876-024-03200-3","volume":"24","author":"H Kranidioti","year":"2024","unstructured":"Kranidioti H, Zisimopoulos K, Oikonomou T, Voulgaris T, Siakavellas S, Agorastou P, Deutsch M, Triantos C, Goulis I, Papatheodoridis G, Manolakopoulos S. Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective-prospective multicenter study. BMC Gastroenterol. 2024;24:133.","journal-title":"BMC Gastroenterol"},{"key":"1584_CR105","first-page":"855","volume":"31","author":"CD Chang","year":"2023","unstructured":"Chang CD, Dong C, Zhao SX, Yuan XW, Zhang XX, Zhao DD, Dou Y, Nan YM. Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2023;31:855\u201361.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"4","key":"1584_CR106","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3904\/kjim.2019.037","volume":"34","author":"JE Song","year":"2019","unstructured":"Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Int Med. 2019;34(4):802.","journal-title":"Korean J Int Med"},{"key":"1584_CR107","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3904\/kjim.2015.30.2.170","volume":"30","author":"YJ Jo","year":"2015","unstructured":"Jo YJ, Kim KA, Lee JS, Kim NH, Bae WK, Song TJ, Kim JW. Long-term virological outcome in chronic hepatitis b patients with a partial virological response to entecavir. Korean J Intern Med. 2015;30:170.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"1584_CR108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.51821\/85.4.10634","volume":"85","author":"ZG Sargin","year":"2022","unstructured":"Sargin ZG, Celik U, Dusunceli I, Ustundag Y. Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience. Acta Gastro-Enterol Belg. 2022;85(4):587\u201392.","journal-title":"Acta Gastro-Enterol Belg"},{"key":"1584_CR109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jvh.13656","volume":"29","author":"YE Chon","year":"2022","unstructured":"Chon YE, Park SY, Kim SU, Hong HP, Lee JS, Lee HW, Kim MN, Park JY, Kim DY, Ahn SH, Kim BK. Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: a multicenter study. J Viral Hepat. 2022;29:289\u201396.","journal-title":"J Viral Hepat"},{"key":"1584_CR110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119:486\u201396.","journal-title":"Am J Gastroenterol"},{"key":"1584_CR111","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MNH.0000000000000907","volume":"32","author":"S Singh","year":"2023","unstructured":"Singh S. Medication safety in chronic kidney disease. Curr Opin Nephrol Hypertens. 2023;32:434\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1584_CR112","doi-asserted-by":"crossref","first-page":"124709","DOI":"10.1016\/j.ijpharm.2024.124709","volume":"665","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang X, Zhao C, Wang S, Lian X, Chen W, He L, Chen M, Wu S, Gong J. Preparation of tenofovir amibufenamide fumarate spherical particles to improve tableting performance and sticking propensity by designing a spherical crystallization process. Int J Pharm. 2024;665:124709.","journal-title":"Int J Pharm"},{"key":"1584_CR113","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/cpt.2184","volume":"109","author":"V Cosson","year":"2021","unstructured":"Cosson V, Feng S, Jaminion F, Lemenuel-Diot A, Parrott N, Paehler A, Bo Q, Jin Y. How semiphysiological population pharmacokinetic modeling incorporating active hepatic uptake supports phase II dose selection of RO7049389, a novel anti\u2013hepatitis B virus drug. Clin Pharm Ther. 2021;109:1081\u201391.","journal-title":"Clin Pharm Ther"},{"key":"1584_CR114","first-page":"381","volume":"8","author":"BC Yoo","year":"2002","unstructured":"Yoo BC, Kim HJ, Do JH, Park SM. Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B. Taehan Kan Hakhoe Chi. 2002;8:381\u20138.","journal-title":"Taehan Kan Hakhoe Chi"},{"key":"1584_CR115","first-page":"48","volume":"40","author":"T Horino","year":"1998","unstructured":"Horino T, Kuriyama S, Tomonari H, Numata M, Hayashi F, Nagata H, et al. Renal damage in a chronic active hepatitis C patient receiving interferon-alpha therapy. Nihon Jinzo Gakkai Shi. 1998;40:48\u201353.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"1584_CR116","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","volume":"21","author":"AL Funk","year":"2021","unstructured":"Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, Chou R, Bulterys M, Shimakawa Y. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21:70\u201384.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1584_CR117","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2169\/internalmedicine.3504-19","volume":"59","author":"M Suoh","year":"2020","unstructured":"Suoh M, Tamori A, Amano-Teranishi Y, Nakai T, Enomoto M, Kawasaki Y, Kioka K, Kawada N. The administration of tenofovir disoproxil fumarate for pregnant Japanese women with chronic hepatitis B. Intern Med. 2020;59(2):205\u201310.","journal-title":"Intern Med"},{"issue":"4","key":"1584_CR118","first-page":"1","volume":"19","author":"L Cao","year":"2023","unstructured":"Cao L, Li S, Dong J, Wen J, Ding L, Ge Y, Yang Q, Xu X, Zhuang H. Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B. Biomed Rep. 2023;19(4):1\u20139.","journal-title":"Biomed Rep"},{"key":"1584_CR119","doi-asserted-by":"crossref","first-page":"15514","DOI":"10.1038\/s41598-018-33833-w","volume":"8","author":"Y Lin","year":"2018","unstructured":"Lin Y, Liu Y, Ding G, Touqui L, Wang W, Xu N, Liu K, Zhang L, Chen D, Wu Y, Bai G. Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep. 2018;8:15514.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"1584_CR120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/liv.13625","volume":"38","author":"S Shan","year":"2018","unstructured":"Shan S, Cui F, Jia J. How to control highly endemic hepatitis B in Asia. Liver Int. 2018;38(Suppl 1):122\u20135.","journal-title":"Liver Int"},{"key":"1584_CR121","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/trstmh\/trad084","volume":"118","author":"P Zhao","year":"2024","unstructured":"Zhao P, Zhao Y, Du M, Chen X, Lu Y. Impact of lamivudine treatment in late pregnancy on the development of the foetal immune response to hepatitis B virus: a meta-analysis in R with the metafor package. Trans R Soc Trop Med Hyg. 2024;118:264\u201372.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1584_CR122","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1080\/21505594.2021.1936769","volume":"12","author":"W Yi","year":"2021","unstructured":"Yi W, Cao X, Zeng Z, Cao W, Zhang Y, Sun F, et al. Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: a prospective study with 3-year follow-up. Virulence. 2021;12:1527\u201337.","journal-title":"Virulence"},{"key":"1584_CR123","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.12499","volume":"29","author":"J Fung","year":"2014","unstructured":"Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29:428\u201334.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"1584_CR124","doi-asserted-by":"crossref","first-page":"772768","DOI":"10.3389\/fphar.2021.772768","volume":"3","author":"R Yang","year":"2022","unstructured":"Yang R, Yin N, Zhao Y, Li D, Zhang X, Li X, Zhang Y, Faiola F. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting system. Front Pharmacol. 2022;3(12):772768.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1584_CR125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12882-024-03537-7","volume":"25","author":"DR Chadwick","year":"2024","unstructured":"Chadwick DR, Barker F, Smith C, Perditer O, Hardy Y, Owusu D, Villa G, Sarfo FS, Geretti AM, Phillips R. Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003\u20132018. BMC Nephrol. 2024;25(1):241.","journal-title":"BMC Nephrol"},{"key":"1584_CR126","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciu734","volume":"59","author":"A Mweemba","year":"2014","unstructured":"Mweemba A, Zanolini A, Mulenga L, Emge D, Chi BH, Wandeler G, Vinikoor MJ. Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults. Clin Infect Dis. 2014;59:1757\u201360.","journal-title":"Clin Infect Dis"},{"key":"1584_CR127","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7196\/SAMJ.2022.v112i2.16188","volume":"112","author":"A Geragotellis","year":"2020","unstructured":"Geragotellis A, Patel S, Sonderup M, Wearne N, Barday Z, Sanglay L, Naicker V, Spearman CW. Tenofovir alafenamide: an initial experience at groote schuur hospital, Cape Town, South Africa. S Afr Med J. 2020;112:113\u20136.","journal-title":"S Afr Med J"},{"key":"1584_CR128","doi-asserted-by":"crossref","first-page":"1185492","DOI":"10.3389\/fmicb.2023.1185492","volume":"25","author":"W Peng","year":"2023","unstructured":"Peng W, Gu H, Cheng D, Chen K, Wu C, Jiang C, Liu J, Peng S, Fu L. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Front Microbiol. 2023;25:1185492.","journal-title":"Front Microbiol"},{"key":"1584_CR129","first-page":"194","volume":"47","author":"W Peng","year":"2022","unstructured":"Peng W, Gu H, Jiang C, Liu J, Zhang J, Fu L. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47:194\u2013201.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"38","key":"1584_CR130","doi-asserted-by":"crossref","first-page":"e27207","DOI":"10.1097\/MD.0000000000027207","volume":"100","author":"J Lei","year":"2024","unstructured":"Lei J, Wang H. Neuromyelitis optica spectrum disorder with active replication of hepatitis B virus and seropositive anti-aquaporin-4 antibody: a case report. Medicine. 2024;100(38):e27207.","journal-title":"Medicine"},{"key":"1584_CR131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-1947-9-1","volume":"9","author":"CF Weng","year":"2015","unstructured":"Weng CF, Chan DC, Chen YF, Liu FC, Liou HH. Chronic hepatitis B infection presenting with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report. J Med Case Rep. 2015;9:1\u20134.","journal-title":"J Med Case Rep"},{"key":"1584_CR132","first-page":"85","volume":"1","author":"E Sinakos","year":"2022","unstructured":"Sinakos E, Panas P, Fragkou N, Antoniadis N, Katsanos G, Tsakni E, Oikonomou T, Notopoulos A, Tsoulfas G, Goulis I, Akriviadis E. Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease. Acta Gastro-Enterol Belg. 2022;1:85.","journal-title":"Acta Gastro-Enterol Belg"},{"key":"1584_CR133","doi-asserted-by":"crossref","first-page":"11335","DOI":"10.3390\/ijms231911335","volume":"23","author":"IC Lee","year":"2022","unstructured":"Lee IC, Lan KH, Su CW, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. Efficacy and renal safety of prophylactic tenofovir alafenamide for HBV-infected cancer patients undergoing chemotherapy. Int J Mol Sci. 2022;23:11335.","journal-title":"Int J Mol Sci"},{"key":"1584_CR134","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/jmv.25211","volume":"90","author":"MDF Xu","year":"2018","unstructured":"Xu MDF, Wang MDC, Shi MDX, Hou MDJ, Guo MDX, Gao MDP. Resolution of HBV infection occurs sooner than recovery of renal disease in adult serum HBsAg-negative HBV\u2013associated glomerulonephritis. J Med Virol. 2018;90:1503\u20137.","journal-title":"J Med Virol"},{"key":"1584_CR135","first-page":"371","volume":"17","author":"YH Sun","year":"2015","unstructured":"Sun YH, Lei XY, Yuan H. Clinical and pathological differences between children with various genotypes of hepatitis B virus-associated glomerulonephritis. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17:371\u20134.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"1584_CR136","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12519-016-0015-0","volume":"12","author":"YH Sun","year":"2016","unstructured":"Sun YH, Lei XY, Sai YP, Chen JH, Sun YC, Gao X. Relationship between genotypes and clinical manifestation, pathology, and cccDNA in Chinese children with hepatitis B virus-associated glomerulonephritis. World J Pediatr. 2016;12:347\u201352.","journal-title":"World J Pediatr"},{"key":"1584_CR137","first-page":"700","volume":"138","author":"N Trehanpati","year":"2013","unstructured":"Trehanpati N, Hissar S, Shrivastav S, Sarin SK. Immunological mechanisms of hepatitis B virus persistence in newborns. Indian J Med Res. 2013;138:700\u201310.","journal-title":"Indian J Med Res"},{"key":"1584_CR138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-018-1108-2","volume":"16","author":"A Luo","year":"2019","unstructured":"Luo A, Jiang X, Ren H. Lamivudine therapy for chronic hepatitis B in children: a meta-analysis. Virol J. 2019;16:1\u20139.","journal-title":"Virol J"},{"key":"1584_CR139","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.21037\/tp-22-496","volume":"12","author":"Y Hu","year":"2023","unstructured":"Hu Y, Wu X, Ye Y, Ye L, Han S, Wang X, Yu H. Liver histological reversibility of lamivudine in treatment-na\u00efve children with chronic hepatitis b: a retrospective cohort study from a single center Shanghai China. Transl Pediatr. 2023;12:1121.","journal-title":"Transl Pediatr"},{"key":"1584_CR140","first-page":"1107675","volume":"33","author":"JY Choe","year":"2018","unstructured":"Choe JY, Ko JS, Choe BH, Kim JE, Kang B, Lee KJ, Yang HR. Antiviral efficacy of tenofovir monotherapy in children with nucleos (t) ide-naive chronic hepatitis B. J Korean Med Sci. 2018;33:1107675.","journal-title":"J Korean Med Sci"},{"key":"1584_CR141","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16134","author":"S Li","year":"2024","unstructured":"Li S, Ouyang W, Yao Z, Lai X, Gu Y, Peng S. Incidence and predictors of HBsAg loss in paediatric patients with chronic hepatitis b undergoing antiviral treatment. Liver Int. 2024. https:\/\/doi.org\/10.1111\/liv.16134.","journal-title":"Liver Int"},{"key":"1584_CR142","doi-asserted-by":"crossref","first-page":"e29670","DOI":"10.1002\/jmv.29670","volume":"96","author":"X Lai","year":"2024","unstructured":"Lai X, OuYang W, Li S, Qiu J, Zhang H, Jiang T, Qin X, Tang L, Gu Y, Yao Z, Peng S. Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B. J Med Virol. 2024;96:e29670.","journal-title":"J Med Virol"},{"key":"1584_CR143","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12887-022-03482-0","volume":"22","author":"Y He","year":"2022","unstructured":"He Y, Zhou Y, Wang H, Peng X, Chang Y, Hu P, Ren H, Xu H. The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B. BMC Pediatr. 2022;22:426.","journal-title":"BMC Pediatr"},{"issue":"1","key":"1584_CR144","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12072-022-10415-7","volume":"17","author":"M Li","year":"2023","unstructured":"Li M, Li Q, Qu J, Yang H, Lv T, Kong Y, Zhang H. The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2023;17(1):52\u201362.","journal-title":"Hepatol Int"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01584-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:02Z","timestamp":1764917282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01584-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"57"}}